Boundless Bio, Inc. (BOLD) Stock Price & Analysis
Boundless Bio, Inc. (BOLD) closed at USD 2.35 on Thursday, October 15, 2026, down 1.67% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.39; the Oct 15, 2026 session ranged USD 2.34–2.53 on volume of 181,876 shares. Market capitalization is $54.31M, with a 52-week range of USD 0.96–3.16 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BOLD.md
Key facts (BOLD)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts), mean target USD 4 (range 4–4).
- Total return with dividends: 1Y +66.7% vs S&P 500 +18.1%; 5Y -83.5% vs S&P 500 +85.1%.
Analysts (BOLD)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts; mean target USD 4 (low 4, high 4).
Total return (dividends reinvested) (BOLD)
| 1Y (from 2025-10-16) | 5Y (from 2024-03-25) | |
|---|---|---|
| Total return | +66.7% | -83.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +67.0% | -50.6% |
| Volatility (annualized) | 78.9% | 83.8% |
| Max drawdown | -30.5% (Oct 2025→Feb 2026) | -92.9% (Mar 2024→Jun 2025) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 2.35 |
|---|---|
| Change | ▼ 1.67% (down) |
| Previous Close | USD 2.39 |
| Open | USD 2.4 |
| Day Range | USD 2.34 – 2.53 |
| 52-Week Range | USD 0.96 – 3.16 |
| Volume | 181,876 shares |
| Market Cap | $54.31M |
| Exchange | NMS |
Technical Analysis (BOLD)
Nexqual's technical model rates BOLD "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.94 (oversold) |
| vs SMA50 | Below (USD 2.75) |
| MACD | -0.09 (negative) |
Analyst Ratings (BOLD)
Wall Street analysts rate BOLD "Hold" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (BOLD)
| EPS Estimate | USD -0.56 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.06 vs est -0.58 ▼ miss |
| 2026-03-31 | USD -0.6 vs est -0.56 ▼ miss |
| 2025-12-31 | USD -0.58 vs est -0.52 ▼ miss |
| 2025-09-30 | USD -0.62 vs est -0.58 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (BOLD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -67.86% |
| Current Ratio | 9.48 |
| Total Cash | $72.63M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (BOLD)
Nexqual rates Boundless Bio, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $73M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$56M (TTM) |
| Efficiency | Critical — ROE -68%, ROA -32.8% |
Ownership (BOLD)
| Insider Ownership | +12.53% |
|---|---|
| Institutional Ownership | +67.26% |
| Shares Outstanding | 23.11M |
| Float | 16.08M |
| Short % of Float | +5.52% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (BOLD)
Boundless Bio, Inc. is led by Jessica Oien (age 54), President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary | Jessica Oien (age 54) |
|---|
Major Backers & Investors (BOLD)
Notable institutional backers of Boundless Bio, Inc. include Arch Venture Management, Llc, FMR, LLC, Tang Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Arch Venture Management, Llc | 11.84% |
| FMR, LLC | 11.35% |
| Tang Capital Management, LLC | 11.25% |
| Adar1 Capital Management, LLC | 8.65% |
| Fidelity | 6.18% |
| Cormorant Asset Management, LP | 4.4% |
| Wellington Management | 2.45% |
| Millennium Management | 2.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.41% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt